About Products & Pipeline Partnering Investors & News Blog Canalevia Canalevia™ (crofelemer delayed-release tablets) is Jaguar’s drug product candidate for chemotherapy-induced diarrhea (CID) in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Jaguar has received Minor Use in a Major Species (MUMS) designation for Canalevia for CID in dogs. Since Jaguar’s July 2017 merger with Napo Pharmaceuticals, Jaguar’s human portfolio has been, and continues to be, our core focus. However, CID is an interesting model for human medical need and is being pursued as our first prescription indication for animal health. We believe there is an important unmet medical need for the treatment of CID in dogs. Certain cancer treatment agents provided to dogs are human drugs, or have the same mechanism of action as human cancer drugs, and these agents and mechanisms of action often have meaningful rates of diarrhea in humans as well. According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost half of dogs over the age of 10 will develop cancer. Due to the increasing number of chemotherapeutic procedures being adopted by veterinarians and veterinary oncologists, chemotherapy is evolving to become the most widely-used oncology treatment modality in veterinary medicine. Moreover, the most prevalent and used targeted chemotherapy, Tyrosine Kinase Inhibitors (TKIs), are widely becoming adopted by small animal practitioners. Chemotherapy-induced diarrhea (CID) is a frequent adverse event in dogs undergoing cancer treatment. Studies have found the incidence of CID to be one of the three most prevalent side effects (1). Adverse events such as diarrhea can result in chemotherapy dose reductions and intermittent treatment that limit the ability of the veterinarian to extract the full benefit of the chemotherapy agent. There currently are no FDA-approved medications for the symptomatic treatment of chemotherapy-induced diarrhea in dogs. Veterinarians typically treat watery diarrhea in dogs with antibiotics, probiotics, dietary restrictions and products approved and formulated for humans, such as Imodium and other anti-motility agents, as well as binding agents that absorb water such as Kaopectate and Pepto-Bismol. None of these treatment options address the water loss associated with watery diarrhea. Jaguar is also pursuing FDA approval for Canalevia for exercise-induced diarrhea (EID) in dogs. Reference: 1 - Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398. © Copyright 2020 Jaguar Health Contact Us | Careers | Legal Notice | Privacy Policy | Social Media Policy | Website Accessibility Feedback Email | Web Accessibility Feedback Form | Admin |